Astragaloside Inhibits Hepatic Fibrosis by Modulation of TGF-β1Smad Signaling Pathway
Joint Authors
Yuan, Xingxing
Gong, Zhiqiang
Wang, Bingyu
Guo, Xueying
Yang, Lei
Li, Dandan
Zhang, Yali
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-04-30
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
Activation of HSC is a pivotal step in hepatic fibrosis.
In the activation of HSC, the TGF-β1 plays a key role that can promote the occurrence of hepatic fibrosis by combining with Smad proteins.
Astragaloside is the main active component extracted from Radix Astragali that has the effect of antioxidation and hepatoprotection.
In the present study, we investigated the mechanism of astragalosides inhibiting hepatic fibrosis in vitro and in vivo.
In vitro, astragalosides inhibited the activation of HSC and regulated the expression of MMP-2 and TIMP-2 and reduced the formation of collagen fibers.
In vivo, administration of astragalosides decreased the serum ALT, AST, and TBiL in rats by reducing oxidative stress.
Astragalosides also attenuated hepatic fibrosis by reducing the concentration of hydroxyproline and inhibiting the formation of collagen fibers.
The expressions of TGF-β1, TβR-I, p-Smad 2, and p-Smad 3 were downregulated after astragalosides treatments, while Smad 7 was upregulated compared to the control group.
The results indicated that the effect of astragaloside on hepatic fibrosis was related to the inhibition of HSC activation and the modulation of the TGF-β1/Smad signaling pathway.
American Psychological Association (APA)
Yuan, Xingxing& Gong, Zhiqiang& Wang, Bingyu& Guo, Xueying& Yang, Lei& Li, Dandan…[et al.]. 2018. Astragaloside Inhibits Hepatic Fibrosis by Modulation of TGF-β1Smad Signaling Pathway. Evidence-Based Complementary and Alternative Medicine،Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1154806
Modern Language Association (MLA)
Yuan, Xingxing…[et al.]. Astragaloside Inhibits Hepatic Fibrosis by Modulation of TGF-β1Smad Signaling Pathway. Evidence-Based Complementary and Alternative Medicine No. 2018 (2018), pp.1-13.
https://search.emarefa.net/detail/BIM-1154806
American Medical Association (AMA)
Yuan, Xingxing& Gong, Zhiqiang& Wang, Bingyu& Guo, Xueying& Yang, Lei& Li, Dandan…[et al.]. Astragaloside Inhibits Hepatic Fibrosis by Modulation of TGF-β1Smad Signaling Pathway. Evidence-Based Complementary and Alternative Medicine. 2018. Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1154806
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1154806